October 13th 2026, 11:05 PM
AI-Powered Obesity Treatment Deal Worth Up to $1.2 Billion
Key Summary
Zealand Pharma has partnered with Generate Biomedicines to develop AI-designed obesity treatments, with total milestone payments reaching up to $1.2 billion. The partnership aims to create multispecific protein therapeutics, which can target multiple biological pathways to treat complex conditions like obesity.
Please see our real time news feed on our Home Page
Introduction
Zealand Pharma has announced a multi-target collaboration and license agreement with Generate Biomedicines to develop AI-designed obesity treatments.Who Does What
Generate's platform pairs generative design with high-throughput experimental validation, using AI to propose new protein structures and test large numbers of them in the lab to see which ones actually work.The Deal
Zealand will pay Generate a $30 million upfront fee, with the option to add a third program. Generate is eligible for up to $35 million in preclinical milestone payments, and will collect tiered royalties based on net sales from the initial programs.Why Zealand Wants This
The partnership fits into Zealand's 'Metabolic Frontier 2030' strategy, aiming to launch multiple programs by 2030 and push the company into new modalities.What This Means
For Generate shareholders, the $30 million upfront payment is the concrete win. Investors should watch for news on the optional third program. For Zealand, the partnership allows the company to pursue differentiation in the crowded obesity treatment market by using multispecific proteins.#BioPharma#AIinPharma#ObesityTreatment#MultispecificProteins